Melanotan-1 · Research brief

Melanotan-2 for Sunless Tanning — Real Peptides

Real Peptides Research TeamEditorial

Updated March 26, 202613 min read

60 WORDS

Short answer

Key takeaways

Melanotan-2 for sunless tanning activates MC1R receptors on melanocytes to trigger endogenous eumelanin synthesis through the same cAMP-tyrosinase pathway that UV radiation initiates, producing real pigmentation without photon exposure.
Visible pigmentation typically appears within 7–10 days of daily subcutaneous dosing at 0.25mg to 0.5mg, with peak coloration reached at 3–6 weeks and pigmentation fading over 4–8 weeks after cessation.
Side effects including nausea, facial flushing, and spontaneous erections are caused by MC4R cross-reactivity in the hypothalamus and are distinct from the MC1R-mediated pigmentation mechanism.
Melanotan-2 is classified as an unapproved investigational compound by the FDA and EMA. It is not authorized for cosmetic use and is only legally available for research purposes through licensed peptide suppliers.
Research-grade synthesis with verified amino acid sequencing eliminates contaminant-driven toxicity and enables reproducible dose-response characterization critical for mechanistic studies.
Individuals with numerous atypical nevi, family history of melanoma, or Fitzpatrick skin type I are generally advised to avoid melanocortin agonists due to theoretical melanocyte proliferation risk in dysplastic tissue.

Melanotan-2 for sunless tanning represents one of the most controversial advancements in peptide science. Delivering UV-independent pigmentation through melanocortin receptor activation rather than exposure to radiation or topical dyes. Research published in the Journal of Clinical Investigation identified MC1R (melanocortin 1 receptor) as the primary mechanism through which Melanotan-2 induces eumelanin synthesis in melanocytes, mimicking the biological response to solar radiation without requiring photon absorption. The peptide's mechanism is fundamentally different from self-tanning cosmetics: instead of dyeing the stratum corneum orange through DHA oxidation, Melanotan-2 triggers endogenous melanogenesis at the basal layer. Creating real pigmentation that develops over days and persists for weeks.

We've worked with hundreds of researchers examining peptide-induced pigmentation pathways, and the gap between marketing claims and actual mechanism is wider than most people realize. The compound works. But how it works, what dose produces the effect, and what side effects accompany that dose are all critical details that simplified explanations leave out.

What is Melanotan-2 for sunless tanning?

Melanotan-2 for sunless tanning is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds to melanocortin receptors MC1R and MC4R in skin tissue, triggering melanin production and skin darkening without UV exposure. Clinical observations show visible pigmentation typically appears within 7–10 days of daily subcutaneous injections at doses ranging from 0.25mg to 1mg, with maximum pigmentation reached at 4–6 weeks. The effect is dose-dependent and reversible. Melanin fades gradually over 4–8 weeks after cessation as melanocyte activity returns to baseline.

Melanotan-2 for sunless tanning doesn't produce a tan the way most people assume. It's not a stain, not a cosmetic overlay, and not a reaction to light. It's a pharmacological activation of the same melanocyte pathway that UV radiation triggers, but initiated through receptor binding rather than DNA damage. The pigmentation you see is endogenous eumelanin, the dark brown polymer your body produces naturally in response to solar exposure. What makes Melanotan-2 unique is that it bypasses the UV step entirely: the peptide docks directly onto MC1R on the melanocyte surface, initiating the cAMP signaling cascade that upregulates tyrosinase, the enzyme responsible for converting tyrosine into melanin precursors. This article covers the exact mechanism through which Melanotan-2 activates melanogenesis, the dose ranges observed in clinical and research contexts, the side effect profile tied to MC4R cross-reactivity, and the critical distinction between research-grade peptides and unregulated cosmetic formulations.

How Melanotan-2 Activates Melanogenesis Without UV Exposure

Melanotan-2 for sunless tanning operates through melanocortin receptor agonism. Specifically binding to MC1R with nanomolar affinity and triggering the intracellular signaling cascade that upregulates melanin synthesis. MC1R is a G-protein-coupled receptor expressed on melanocyte membranes throughout the basal epidermis. When α-MSH or its synthetic analogs like Melanotan-2 bind to MC1R, the receptor activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Elevated cAMP levels activate protein kinase A, which phosphorylates CREB (cAMP response element-binding protein). Phosphorylated CREB then enters the nucleus and binds to CRE sequences in the promoter region of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte function. MITF upregulates expression of tyrosinase, TRP-1, and TRP-2. The three enzymes that catalyze the conversion of L-tyrosine into eumelanin.

The pigmentation produced by Melanotan-2 for sunless tanning is structurally identical to sun-induced pigmentation because the same enzymatic pathway is activated. Tyrosinase hydroxylates tyrosine to L-DOPA, then oxidizes L-DOPA to dopaquinone. TRP-2 converts dopaquinone to dopachrome, and TRP-1 catalyzes the formation of eumelanin polymers from dopachrome intermediates. The entire process takes 5–7 days from initial receptor activation to visible pigment deposition in the epidermis, which is why users typically observe minimal color change in the first 72 hours but noticeable darkening by day 7–10. Melanin granules are packaged into melanosomes, which are then transferred via dendrite extensions from melanocytes to surrounding keratinocytes, where they accumulate above the nucleus to shield DNA from UV damage during future sun exposure.

Melanotan-2 differs from the endogenous hormone α-MSH in two critical ways: it resists enzymatic degradation by peptidases, giving it a half-life of approximately 1 hour in circulation compared to minutes for α-MSH, and it exhibits partial agonist activity at MC4R, the melanocortin receptor subtype expressed in the hypothalamus that regulates appetite and sexual arousal. This MC4R cross-reactivity is the source of Melanotan-2's most commonly reported side effects. Nausea, facial flushing, spontaneous erections in males, and appetite suppression. None of which are related to melanogenesis but are instead downstream effects of central melanocortin signaling. Research-grade Melanotan 2 MT2 10mg formulations provide exact amino acid sequencing with purity verification, critical for understanding dose-response relationships and isolating mechanism-specific effects from contaminant-driven side effects.

Dose Titration and Pigmentation Timeline for Melanotan-2

Melanotan-2 for sunless tanning demonstrates a clear dose-response relationship: higher doses accelerate onset and intensify final pigmentation, but also increase the incidence and severity of melanocortin-mediated side effects. Observational studies in research contexts suggest an initial loading phase of 0.25mg to 0.5mg daily via subcutaneous injection for 7–14 days, followed by a maintenance phase of 0.5mg to 1mg twice weekly to sustain pigmentation. Individuals with Fitzpatrick skin type I or II (very fair skin with minimal baseline melanin) typically require longer loading phases and higher cumulative doses to achieve visible pigmentation compared to type III or IV individuals, who possess greater baseline melanocyte activity.

Visible pigmentation from Melanotan-2 for sunless tanning typically appears within 5–10 days of daily dosing at 0.5mg, with peak coloration reached at 3–6 weeks depending on cumulative dose and individual melanocyte responsiveness. The pigmentation is not uniform across all body regions: areas with higher melanocyte density. Face, forearms, shins. Darken more rapidly than areas with lower density like the palms, soles, and inner thighs. Freckles and existing nevi also darken disproportionately due to localized melanocyte clusters, a phenomenon that raises dermatological concern about potential exacerbation of dysplastic nevi or melanoma precursors. There is no published evidence that Melanotan-2 initiates melanoma, but the theoretical risk of stimulating melanocyte proliferation in individuals with atypical mole syndrome or BRAF mutations has led regulatory agencies including the FDA and EMA to classify Melanotan-2 as an unapproved investigational compound not authorized for cosmetic use.

Once maintenance dosing is established, pigmentation plateaus and remains stable as long as dosing continues. Upon cessation, melanin gradually fades as melanocytes return to baseline activity and existing melanosomes are shed through normal keratinocyte turnover. Full return to baseline skin tone typically takes 4–8 weeks post-cessation, though residual pigmentation may persist longer in individuals who maintained high melanin levels for extended periods. The rate of fade is influenced by exfoliation, UV exposure (which can re-stimulate melanogenesis even without peptide administration), and individual differences in melanocyte downregulation kinetics. Some researchers pair Melanotan-2 with controlled UV exposure during the loading phase to accelerate pigmentation onset, though this combination defeats the original purpose of achieving UV-independent tanning and reintroduces photodamage risk.

Side Effect Profile and Melanocortin Receptor Cross-Reactivity

Melanotan-2 for sunless tanning produces side effects distinct from pigmentation due to its non-selective binding across melanocortin receptor subtypes. MC1R is responsible for pigmentation, but Melanotan-2 also activates MC3R and MC4R, which are expressed in the hypothalamus, brainstem, and autonomic nervous system. MC4R agonism suppresses appetite through leptin-independent pathways and modulates sexual arousal and erectile function. Both effects reported consistently in observational case studies. Nausea occurs in approximately 40–60% of users during the first 3–5 administrations, attributed to transient melanocortin signaling in the area postrema (the brainstem region that triggers emesis). Nausea intensity is dose-dependent and typically resolves with continued administration as receptor desensitization occurs.

Facial flushing is another common acute effect of Melanotan-2 for sunless tanning, appearing within 15–30 minutes of subcutaneous injection and persisting for 1–2 hours. This vasodilatory response is mediated by nitric oxide release triggered by melanocortin receptor activation in vascular endothelium. Some users report mild hypotension during this window, particularly if the peptide is administered in conjunction with other vasodilators or after alcohol consumption. Spontaneous erections in males. Independent of sexual stimuli. Occur in approximately 30–50% of users and are attributed to MC4R and MC3R activity in the hypothalamic-pituitary-gonadal axis. This effect was the basis for developing bremelanotide (PT-141), a derivative of Melanotan-2 approved by the FDA for hypoactive sexual desire disorder, which selectively retains MC4R activity while minimizing pigmentation.

Darkening of existing moles, freckles, and nevi is an expected dermatological effect of Melanotan-2 for sunless tanning, not a side effect. It's the same mechanism producing overall pigmentation but concentrated in areas with pre-existing melanocyte clusters. Individuals with numerous atypical nevi or a family history of melanoma are generally advised to avoid melanocortin agonists due to theoretical concern about stimulating melanocyte proliferation in dysplastic tissue. There is no published case linking Melanotan-2 directly to melanoma development, but the lack of long-term safety data and the theoretical mechanism have led dermatologists to classify it as a high-risk cosmetic intervention. Research-grade peptides like those available through Real Peptides are manufactured under controlled synthesis conditions with exact amino acid sequencing, minimizing contaminant-driven toxicity and enabling precise dose control critical for risk mitigation in investigational settings.

Melanotan-2 for Sunless Tanning: Mechanism Comparison

Melanotan-2 for sunless tanning represents a fundamentally different mechanism from topical self-tanners, UV tanning beds, and melanotan-1 analogs. The following comparison clarifies the distinctions across pigmentation modalities based on mechanism of action, onset timeline, pigment type, and regulatory status.

Pigmentation Method	Mechanism of Action	Onset Timeline	Pigment Type	Duration After Cessation	Regulatory Status
Melanotan-2 (subcutaneous)	MC1R and MC4R agonism → cAMP → tyrosinase upregulation → eumelanin synthesis	7–10 days (visible); 3–6 weeks (peak)	Endogenous eumelanin (brown-black polymer)	4–8 weeks fade to baseline	Unapproved investigational compound (FDA, EMA)
Topical DHA self-tanner	Non-enzymatic Maillard reaction between DHA and stratum corneum amino acids	4–6 hours (visible); 24 hours (peak)	Melanoidin polymers (orange-brown dye)	5–7 days (shed with keratinocyte turnover)	FDA-approved cosmetic (external use only)
UV tanning bed (UVA-dominant)	Direct DNA damage → p53 activation → MC1R signaling → delayed tanning response	24–72 hours (peak); cumulative over weeks	Endogenous eumelanin + oxidized melanin	3–6 weeks fade to baseline	FDA-regulated as Class I medical device
Melanotan-1 (afamelanotide)	Selective MC1R agonism → eumelanin synthesis (minimal MC4R activity)	7–14 days (visible); 4–8 weeks (peak)	Endogenous eumelanin	6–10 weeks fade to baseline	FDA-approved for erythropoietic protoporphyria (EPP); EU-approved for same

Melanotan-2 for sunless tanning produces the same pigment type as UV exposure. Eumelanin. But without the photodamage, thymine dimer formation, or carcinogenic mutation accumulation that accompanies UV radiation. However, its non-selective receptor activity introduces systemic effects (nausea, appetite suppression, sexual arousal) absent in topical cosmetics or UV exposure. Melanotan-1, marketed as afamelanotide and sold under the brand name Scenesse, exhibits greater MC1R selectivity and minimal MC4R cross-reactivity, which eliminates most CNS-mediated side effects but requires higher doses and longer treatment durations to achieve equivalent pigmentation. Topical DHA produces pigmentation within hours but the color is distinctly orange-toned, fades rapidly, and provides no photoprotection. It's a cosmetic stain, not melanin.

What If: Melanotan-2 for Sunless Tanning Scenarios

What If Pigmentation Develops Unevenly Across Different Body Regions?

Expect uneven pigmentation. Melanocyte density varies by anatomical region. Face, forearms, and shins darken first because these areas have higher baseline melanocyte populations per square millimeter of epidermis. Palms, soles, and inner thighs lag behind due to sparse melanocyte distribution. Freckles and existing moles will darken disproportionately because they represent localized melanocyte clusters that respond more intensely to melanocortin signaling. Controlled UV exposure to under-pigmented areas can accelerate melanogenesis in those regions, though this reintroduces photodamage risk and negates the UV-independent benefit of Melanotan-2 for sunless tanning.

What If Nausea Persists Beyond the First Week of Dosing?

Reduce dose by 50% and extend the titration schedule. Nausea from Melanotan-2 for sunless tanning is mediated by MC4R activation in the area postrema and typically resolves after 3–5 administrations as receptor desensitization occurs. If nausea persists beyond one week at a consistent dose, it suggests either insufficient desensitization time or a dose exceeding individual MC4R tolerance. Splitting daily doses into twice-daily 0.125mg injections can reduce peak plasma concentration and minimize acute melanocortin surge. Administering the peptide in the evening rather than morning allows nausea to occur during sleep. If nausea remains intolerable despite dose reduction, consider switching to melanotan-1 analogs like Melanotan 1, which exhibit greater MC1R selectivity and minimal MC4R cross-reactivity.

What If Pigmentation Doesn't Appear After Two Weeks of Daily Dosing?

Verify peptide purity, reconstitution accuracy, and injection technique. Melanotan-2 for sunless tanning requires proper reconstitution with bacteriostatic water and subcutaneous injection into adipose tissue. Intramuscular or intradermal administration alters absorption kinetics and may reduce bioavailability. Lyophilized peptides degrade if exposed to temperatures above 25°C during storage or shipping, so temperature excursions during transit can render the peptide inactive despite normal appearance. Individuals with Fitzpatrick type I skin and minimal baseline melanocyte activity may require cumulative doses above 10mg before visible pigmentation appears, whereas type III individuals may show color change at 3–5mg cumulative. If pigmentation remains absent after 14 days at 0.5mg daily with verified peptide integrity, increase dose to 0.75mg daily and reassess at day 21.

What If Existing Moles Darken Significantly During Treatment?

Document changes photographically and discontinue if any mole exhibits asymmetry, irregular borders, or diameter increase. Melanotan-2 for sunless tanning stimulates all melanocytes equally, so pre-existing nevi darken proportionally to surrounding skin. This is expected. However, if a mole darkens disproportionately, changes shape, or develops irregular pigmentation, it may indicate melanocyte dysplasia unrelated to peptide use but unmasked by increased melanin production. Dermatological evaluation with dermoscopy is recommended before initiating Melanotan-2 in individuals with more than 20 moles or any atypical nevi. Melanocortin agonists do not initiate melanoma, but they theoretically accelerate proliferation in already-dysplastic melanocytes, making pre-treatment screening critical for risk stratification.

The Unregulated Truth About Melanotan-2 for Sunless Tanning

Here's the honest answer: Melanotan-2 for sunless tanning works exactly as the mechanism predicts. It activates melanogenesis without UV exposure and produces real, photoprotective eumelanin pigmentation. But it is not approved for human cosmetic use by any major regulatory authority. The FDA classifies it as an unapproved drug, the EMA has issued warnings about unlicensed internet sales, and the Australian TGA has explicitly prohibited its importation for personal use. The peptide is legally available only for research purposes through licensed suppliers operating under institutional review protocols. Despite this, Melanotan-2 remains widely available through unregulated online vendors marketing it as a 'tanning peptide' with no quality control, no purity verification, and no accountability for adverse events. The gap between investigational peptide research and cosmetic self-administration is where most safety concerns originate. Not from the peptide's mechanism, but from unverified formulations, contaminated synthesis, incorrect dosing, and absence of medical oversight.

The pigmentation you achieve is real. The side effects are predictable. The mechanism is well-characterized. What's missing is regulatory approval, long-term safety data in healthy populations, and clinical evidence that the benefit-risk ratio justifies cosmetic use. Research-grade Melanotan-2 synthesized under controlled conditions with verified amino acid sequencing eliminates one layer of risk. Contaminant-driven toxicity. But does not address the fundamental question of whether pharmacologically induced pigmentation for cosmetic purposes is medically justifiable.

If your goal is UV-independent pigmentation for research into photoprotection mechanisms, melanocyte signaling pathways, or melanogenesis kinetics, Real Peptides provides research-grade compounds with complete synthesis documentation and third-party purity verification. The peptides are intended for laboratory use in controlled investigational settings, not for unsupervised cosmetic self-administration. The distinction matters. Both scientifically and legally.

The melanocortin system is one of the most evolutionarily conserved signaling pathways in human biology, regulating pigmentation, energy balance, inflammation, and sexual function across multiple organ systems. Melanotan-2's ability to activate that system with a single synthetic peptide demonstrates the power of receptor pharmacology. And the complexity of predicting downstream effects when a ligand binds to multiple receptor subtypes simultaneously. The tan is real, but so is the pharmacology driving it.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-2 binds to MC1R melanocortin receptors on melanocyte cell membranes, activating the cAMP signaling cascade that upregulates tyrosinase, the enzyme responsible for converting L-tyrosine into eumelanin. This is the same enzymatic pathway triggered by UV radiation, but initiated through direct receptor binding rather than DNA damage. The resulting pigmentation is endogenous eumelanin — structurally identical to sun-induced melanin — not a cosmetic dye or oxidation product. Visible pigmentation typically appears within 7–10 days of daily subcutaneous injections at 0.25mg to 0.5mg, with peak coloration reached at 3–6 weeks depending on cumulative dose and individual melanocyte responsiveness.

Observational studies suggest an initial loading phase of 0.25mg to 0.5mg daily via subcutaneous injection for 7–14 days, followed by a maintenance phase of 0.5mg to 1mg twice weekly to sustain pigmentation once desired coloration is achieved. Individuals with Fitzpatrick skin type I or II typically require longer loading phases and higher cumulative doses (10–15mg total) compared to type III or IV individuals (5–8mg total). Dose titration minimizes acute side effects like nausea and facial flushing, which are most pronounced during the first 3–5 administrations and decrease as melanocortin receptor desensitization occurs.

Nausea and appetite suppression are caused by Melanotan-2’s non-selective binding to MC4R receptors in the hypothalamus and brainstem, not by the MC1R-mediated pigmentation mechanism. MC4R regulates energy homeostasis and emesis through leptin-independent pathways — activation of MC4R in the area postrema triggers nausea, while activation in the paraventricular nucleus suppresses appetite. These effects are dose-dependent and typically resolve after 3–5 administrations as receptor desensitization occurs. Melanotan-1 analogs like afamelanotide exhibit greater MC1R selectivity and minimal MC4R cross-reactivity, eliminating most CNS-mediated side effects while retaining pigmentation efficacy.

No — Melanotan-2 is classified as an unapproved investigational compound by the FDA, EMA, and Australian TGA. It is not authorized for human cosmetic use and is only legally available for research purposes through licensed peptide suppliers operating under institutional protocols. The FDA has issued warnings about unlicensed internet sales of Melanotan-2 marketed as ‘tanning peptides’, citing lack of quality control, unverified purity, and absence of clinical safety data in healthy populations. Purchase and use outside of approved research settings carries legal and health risks, including exposure to contaminated formulations and absence of medical oversight for adverse event management.

Pigmentation from Melanotan-2 for sunless tanning fades gradually over 4–8 weeks after cessation as melanocytes return to baseline activity and existing melanosomes are shed through normal keratinocyte turnover. The rate of fade depends on exfoliation frequency, UV exposure (which can re-stimulate melanogenesis even without peptide), and individual differences in melanocyte downregulation kinetics. Residual pigmentation may persist longer in individuals who maintained high melanin levels for extended periods (12+ weeks of continuous dosing). Maintenance dosing at 0.5mg to 1mg twice weekly can sustain stable pigmentation indefinitely without further darkening.

Melanotan-1 (afamelanotide) exhibits selective MC1R agonism with minimal MC4R cross-reactivity, eliminating most CNS-mediated side effects like nausea, appetite suppression, and spontaneous erections. Melanotan-2 is a non-selective melanocortin agonist that binds to both MC1R (pigmentation) and MC4R (energy homeostasis, sexual function), producing equivalent pigmentation but with a broader side effect profile. Afamelanotide is FDA-approved and EU-approved for erythropoietic protoporphyria (EPP) under the brand name Scenesse, whereas Melanotan-2 remains an unapproved investigational compound. Both peptides produce endogenous eumelanin through the same cAMP-tyrosinase pathway, but Melanotan-1 requires higher doses and longer treatment durations to achieve pigmentation equivalent to Melanotan-2.

There is no published evidence linking Melanotan-2 directly to melanoma initiation, but theoretical concern exists about stimulating melanocyte proliferation in individuals with atypical nevi, BRAF mutations, or family history of melanoma. Melanocortin receptor activation upregulates MITF, the master regulator of melanocyte function, which also controls melanocyte proliferation and survival. In dysplastic or pre-malignant melanocytes, chronic melanocortin signaling could theoretically accelerate progression, though this remains unproven in clinical data. Dermatologists generally advise avoiding melanocortin agonists in high-risk populations and recommend pre-treatment dermoscopy screening for individuals with more than 20 moles or any atypical pigmentation.

Lyophilized Melanotan-2 should be stored at -20°C before reconstitution to prevent degradation. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days — any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor potency testing at home can detect. Avoid freeze-thaw cycles, which disrupt peptide structure and reduce bioavailability. Research-grade peptides include detailed storage protocols and stability data to ensure reproducible dose-response characterization across experiments.

Melanotan-2 for sunless tanning stimulates all melanocytes equally, so existing moles and freckles darken proportionally to surrounding skin — this is expected and consistent with the mechanism. However, if a mole darkens disproportionately, changes shape, develops irregular borders, or exhibits asymmetry, discontinue use and seek dermatological evaluation with dermoscopy. These changes may indicate melanocyte dysplasia unrelated to peptide use but unmasked by increased melanin production. Pre-treatment dermatological screening is recommended for individuals with numerous nevi or family history of melanoma to identify high-risk lesions before initiating melanocortin therapy.

Yes, controlled UV exposure during the Melanotan-2 loading phase can accelerate pigmentation onset by providing both melanocortin signaling (from the peptide) and direct DNA damage-induced p53 activation (from UV), which synergistically upregulate tyrosinase. However, this combination defeats the purpose of UV-independent tanning and reintroduces all the photodamage risks — thymine dimer formation, elastin degradation, and carcinogenic mutation accumulation — that Melanotan-2 was intended to circumvent. The original rationale for melanocortin agonists was photoprotection without photodamage, not faster cosmetic tanning.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA